All articles by

US FDA approves Italfarmaco’s Duvyzat to treat DMD in children and adults

The FDA approval is supported by the results from EPIDYS, a randomized, double-blind, placebo-controlled 18-month Phase 3 clinical trial, which met its primary endpoint, and favourable results on key secondary endpoints

Lonza to buy Genentech’s biologics manufacturing site in California for $1.2bn

The deal is anticipated to boost Lonza’s large-scale biologics manufacturing capacity and will also help the firm cope with the demand for commercial mammalian contract manufacturing

AstraZeneca to acquire Canadian cancer drugmaker Fusion for $2bn

The transaction complements AstraZeneca’s oncology portfolio with Fusion’s pipeline of RCs, including its lead programme FPI-2265, and replaces the traditional chemotherapy and radiotherapy with more targeted treatments

Microbix’s Clot-Buster Drug Project Advances

Sequel Pharma Executes Agreement with CDMO for Drug Substance Production

Optinose gets FDA nod for Xhance in chronic rhinosinusitis without nasal polyps

Xhance is a drug-device combination product that utilises the Exhalation Delivery System engineered to administer a topical steroid to the intricate and deep regions of the nasal cavity crucial for sinus ventilation and drainage

AstraZeneca to acquire French drugmaker Amolyt Pharma for $1.05bn

AstraZeneca said that the acquisition will further expand the pipeline of Alexion, AstraZeneca Rare Disease, beyond complement inhibition, building on its success in bone metabolism and opportunity in rare endocrinology

Pearl Bio teams up with Merck to discover novel engineered biologics

The collaboration will initially focus on the discovery and development of biologic therapies for the treatment of cancer using Pearl’s exclusive GRO technology, which facilitates working in both cell-based and cell-free systems

Dassault Systèmes to support CDR-Life in development of cancer therapies

Under the partnership, Dassault Systèmes, a science-based firm with virtual twin experiences, and CDR-Life will study the stability of antibody-based biologics known as T-cell engagers

Cellares introduces cGMP-compliant Cell Shuttle for cell therapy manufacturing

The Cell Shuttle is an automated, ultra-high throughput, manufacturing platform designed to address the global patient demand while lowering process failure rates and costs

GV20 Therapeutics Joins NVIDIA Inception to Develop AI Models for Drug and Target Discovery

GV20 Therapeutics will leverage the resources provided by NVIDIA Inception to develop new AI models for drug discovery, focused on novel therapeutic antibodies